PTC Therapeutics, Inc.

Healthcare

NASDAQ:PTCT · NASDAQ Global Select

Market Cap $6.20B Beta 0.55 P/E (TTM) -33.2

$75.14 +0.57%

+$0.42 today

52W Low $43.18High $87.50

Vol 1.07M · Avg 1.22M

EPS (TTM)-$2.26

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+46.59%

Period High

$86.25

Period Low

$43.30

Latest

$75.14

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

$10.46B

Krystal Biotech, Inc.

NASDAQ:KRYS

$9.39B

TG Therapeutics, Inc.

NASDAQ:TGTX

$7.58B

Metsera, Inc.

MTSR

$7.43B

Alkermes plc

NASDAQ:ALKS

$7.43B

Protagonist Therapeutics, Inc.

NASDAQ:PTGX

$7.10B

Vaxcyte, Inc.

NASDAQ:PCVX

$6.87B

Arcellx, Inc.

ACLX

$6.73B

Crinetics Pharmaceuticals, Inc.

NASDAQ:CRNX

$3.67B

Atrium Therapeutics, Inc.

NASDAQ:RNA

$210.06M

What is the latest PTCT filing?

The latest filing shown is 8-K dated Jun 9, 2026.

How many recent filings does PTCT have?

Intrinsic Alpha currently shows 20 recent filings for PTCT.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.